Short Interest in Check-Cap Ltd (NASDAQ:MBAI) Declines By 63.5%

Check-Cap Ltd (NASDAQ:MBAI) was the recipient of a significant decline in short interest in May. As of May 29th, there was short interest totaling 65,685 shares, a decline of 63.5% from the May 14th total of 180,004 shares. Based on an average trading volume of 73,927 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.9% of the shares of the stock are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Check-Cap in a research report on Friday, April 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company has a consensus rating of “Sell”.

Check-Cap Price Performance

Check-Cap stock traded up $0.02 during midday trading on Friday, hitting $1.39. The company’s stock had a trading volume of 31,129 shares, compared to its average volume of 70,794. The business’s 50-day simple moving average is $1.64. Check-Cap has a 12 month low of $0.59 and a 12 month high of $3.92. The firm has a market capitalization of $10.13 million, a P/E ratio of -0.50 and a beta of 0.59.

Check-Cap Company Profile

Check-Cap Ltd. (NASDAQ: MBAI) is an Israel-based medical technology company focused on non-invasive screening solutions for colorectal cancer. The company develops an ingestible imaging capsule and associated detection system intended to provide a patient-friendly alternative to traditional colonoscopy and CT colonography for colorectal screening and polyp detection.

Check-Cap’s technology centers on a swallowable capsule that acquires images of the colon as it traverses the gastrointestinal tract; external detectors capture the transmitted signals and software reconstructs images for clinical review.